Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol for Treatment-resistant Major Depressive Disorder
NCT04680910Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propofol injection (veterinary) in treatment-resistant depression (TRD), sponsored by Washington University School of Medicine. Primary endpoints: Number of Participants Without Serious Adverse Events During Propofol Infusions at 1 week, Change in SWA During Propofol Infusions Compared to Awake Baseline Before Infusion at 2 hours and 1 more. Started Jan 2021; status: completed.
02
Drugs
propofol injection (veterinary)
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04680910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680910.